This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           April 29, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Removing ovaries during breast cancer could save lives, new research says
In women who have both breast cancer and the BRCA1 mutation, having surgery to remove the ovaries can significantly lower their risk of dying from the disease, suggests a new study published in the journal JAMA Oncology. Women with BRCA1 or BRCA2 genetic mutations have up to a 70 percent risk of getting breast cancer and a high risk for ovarian cancer. Now, a new study shows that for women who already have cancer and have a BRCA1 mutation, surgery to remove ovaries could lower the risk of dying of breast cancer by 62 percent.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


ESGO's 19th International Meeting Oct. 24-27 in Nice
The 19th International Meeting of the European Society of Gynaecological Oncology (ESGO) convenes on Oct. 24-27, 2015, in Nice, France. Over 2500 participants are expected to attend and the CME-accredited congress will feature an exclusive keynote lecture on image-guided surgery presented by Professor Jacque Marescaux, founder of the Research Institute Against Digestive Cancer (IRCAD) in Strasbourg, France. The abstract submission deadline is May 5; early registration deadline is July 7. Learn more about the ESGO meeting here.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Algorithm helps surgeons remove all visible ovarian tumors
Clinical Oncology
A surgical algorithm developed and implemented by ovarian cancer specialists at the University of Texas MD Anderson Cancer Center in Houston dramatically increased the frequency of optimal resection, a milestone strongly tied to improved survival during to a recent study published in Nature Reviews. “Our algorithm allows us to be much smarter about whom we operate on up front, providing a more individualized approach to surgery that’s led to better results for our patients,” said investigator Anil Sood, MD, a professor of gynecologic oncology and reproductive medicine and the lead investigator of the study.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Evidence points to fallopian-tube origins of ovarian cancer
Medscape (Free login required)
Most cases of high-grade serous cancer (HSGC) ― the most lethal form of ovarian cancer ― arise from the fallopian tubes rather than the ovaries, concludes a literature review published in the April issue of Cancer Prevention Research. "There has been a major breakthrough in our understanding of the origin of ovarian cancer with the identification of the fallopian tubes as the major source of the cancer," commented first author Mary Daly, MD, head of the Genetics Risk Assessment Division of Fox Chase Cancer Center in Philadelphia, PA.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Combined brachytherapy techniques should be 'benchmark' for cervical cancer treatment
Science Daily
The first large international study, presented at the European Society for Radiotherapy and Oncology Forum April 25 in Barcelona, Spain, to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to the tumor without an increase in treatment-related problems afterwards. New research suggests that the technique should be the benchmark” for treatment of the disease.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.

Top 5 lessons learned at SGO's Women's Cancer Annual Meeting
Surgical and medical approaches to ovarian cancer, sentinel node mapping for endometrial cancer, the use of tissue morcellation for uterine tissue extraction, and the 9-Valent HPV vaccine were among the key topics presented at the 2015 Society of Gynecologic Oncology’s Women’s Cancer Annual Meeting. “We heard presentations from various speakers on topics that have generated great excitement,” Nadeem R. Abu-Rustum, MD, meeting program committee chair, told HemOnc Today. “We heard some encouraging findings, and some interesting debates.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Health insurance coverage among cancer patients varies greatly by demographics and cancer type
Science Daily
Among patients with cancer, rates of health insurance coverage vary by patient demographics and by cancer type, a new analysis published in Cancer has found. The researchers found that younger, non-white, unmarried patients residing in counties with higher levels of poverty and in rural areas were less likely to have insurance. Moreover, males were less likely to have insurance than females, and people residing in Southern states were less likely to have insurance than people residing in other areas of the country. Also, there was large variation in insurance rates by cancer type, with the highest uninsured rates in testicular, stomach, and cervical cancers, and the lowest uninsured rates in thyroid, prostate and breast cancers.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Visit the SGO Women's Cancer News archive page.

Newt Gingrich: Double the NIH budget
The New York Times (Opinion)
No one who lived through the 1990s would have suspected that one day people would look back on the period as a golden age of bipartisan cooperation. But in some important ways, it was. Amid the policy fights that followed the Republican victories of 1994, President Bill Clinton and the new majorities in Congress reached one particularly good deal: doubling the budget for the National Institutes of Health.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Eligible for breast conserving therapy, many still choose mastectomy
Health Canal
No approved targeted therapies exist to treat triple-negative breast cancer, but new chemotherapeutic treatment strategies are helping shrink tumors so that less breast tissue needs to be removed during surgery. New research led by Brigham and Women’s Hospital finds that breast-conserving therapy – or the removal of less breast tissue via a lumpectomy – was successful in more than 90 percent of the women who became eligible for this procedure after treatment with chemotherapy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

April 22, 2015
April 15, 2015
April 8, 2015
April 1, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063